Evidence map›Paper›PMID 40162019›Full record

ReviewRegenerative therapy2025

Navigating mesenchymal stem cells doses and delivery routes in heart disease trials: A comprehensive overview.

Mohammad Reza Khalili, Salma Ahmadloo, Seyed Amin Mousavi, Mohammad Taghi Joghataei, Peiman Brouki Milan, Soheila Naderi Gharahgheshlagh, Seyedeh Lena Mohebi, Seyed Mohammad Amin Haramshahi, Vahid Hosseinpour Sarmadi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad Reza KhaliliBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Salma AhmadlooInstitute for Cognitive and Brain Science, Shahid Beheshti University, Tehran, Iran.
Seyed Amin MousaviDepartment of Plastic and Reconstructive Surgery, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Taghi JoghataeiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Peiman Brouki MilanCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Soheila Naderi GharahgheshlaghBurn Research Center, Iran University of Medical Sciences, Tehran, Iran.
Seyedeh Lena MohebiInstitutes of Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad Amin HaramshahiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Vahid Hosseinpour SarmadiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, various clinical trials have been designed and implemented using mesenchymal stem cells (MSCs) for the treatment of heart diseases. Clinical trials exploring MSC-based treatments have proliferated, yet the lack of standardized protocols for MSC administration remains a significant challenge. Despite the growing popularity of MSC trials, questions persist regarding optimal dosing, administration routes, and frequency to achieve safety and efficacy, particularly in the context of cardiac regeneration. The current study has reviewed the clinical trials that have used MSCs for the treatment of heart diseases since 2009. The findings reveal diverse transplantation methods and varying MSCs quantities, highlighting the absence of a universal guideline for MSCs utilization in heart disease clinical trials.

Indexed as

Administration routesClinical trialHeart diseasesMesenchymal stem cellsOptimal doses

Identifiers

PMID40162019
PMCPMC11952810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.